on Gemina Laboratories Ltd. (isin : CA3686501071)

Gemina Laboratories Strategic Update

Gemina Laboratories Ltd (CSE:GLAB) has announced significant progress in H1 2024, including key licensing deals and new revenue streams. The company signed its first license deal with a global diagnostics company in April, validating its technology after extensive evaluation. Additionally, four other diagnostic companies have signed Non-Disclosure Agreements with Gemina.

Gemina issued its first commercial invoice in June 2024, anticipating maiden revenues in H2 and ramping up in 2025. The company’s R&D team has developed 34 inventions, notably pioneering the use of cellulose for lateral flow tests.

Gemina is exploring markets beyond point-of-care diagnostics, estimating a $7B addressable market. Plans to open a new GMP protein production facility in Vancouver by August are on track.

The company has also commenced trading on the OTCQB Market in the US, expanding its public market exposure.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Gemina Laboratories Ltd. news